CAIGAN study protocol: complement activation in primary IgA nephropathy—study protocol for an international prospective multicenter observational cohort study

Abstract Background IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide and a leading cause of chronic kidney disease and kidney failure. Increasing evidence supports a central role for complement activation in disease severity and crescent formation. With the emergence of complement-targeted therapies, biomarkers identifying patients with active complement dysregulation are increasingly needed. Methods CAIGAN (Complement Activation in IgA Nephropathy) is an international, prospective, observational multicenter cohort study involving adult and pediatric nephrology centers in Switzerland, Italy, France, and Spain. Consecutive patients undergoing clinically indicated native kidney biopsy for suspected IgAN will be screened, and those with biopsy-proven primary IgAN will be enrolled. Clinical and laboratory follow-up data will be collected from routine care every six months for three years, with additional three-month data included where available. Blood and urine samples for complement analyses will generally be obtained after histopathological confirmation of IgAN, within 4 weeks after kidney biopsy and before initiation of immunosuppressive therapy. In patients with a rapidly progressive clinical course requiring prompt immunosuppressive treatment, sampling may precede histopathological confirmation and will be performed after informed consent and before administration of immunosuppressive agents. Complement profiling will include circulating complement proteins and activation products, functional pathway assessment, and complement-related genetic analyses. Kidney biopsies will be characterized using the Oxford MEST-C classification, with intrarenal complement deposition assessed in a subgroup. The primary objective is to validate prospectively the association observed in our retrospective pilot study between circulating sC5b-9 concentrations and the percentage of active glomerular crescents. Secondary exploratory objectives include characterization of the mechanisms underlying complement activation and dysregulation and evaluation of their associations with clinical phenotype, histopathological findings, renal tissue complement activation, genetic profiles, and longitudinal kidney outcomes. Discussion CAIGAN will integrate complement phenotyping, genetics, histopathology, and prospective clinical follow-up to characterize complement activation across the spectrum of primary IgAN and possibly support the development of biomarker-guided therapeutic strategies.

Authors

Institutions

Publication Details

Journal
BMC Nephrology
Published
2026-11-17
DOI
https://doi.org/10.1186/s12882-026-05502-y
Primary Topic
Renal Diseases and Glomerulopathies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

CAIGAN study protocol: complement activation in primary IgA nephropathy—study protocol for an international prospective multicenter observational cohort study

Lorenzo Berwert, Lauréane Mittaz‐Crettol, Licia Peruzzi, Nathalie Felix et al.
1 links
BMC Nephrology
Renal Diseases and Glomerulopathies
article

CAIGAN study protocol: complement activation in primary IgA nephropathy—study protocol for an international prospective multicenter observational cohort study

Lorenzo Berwert, Lauréane Mittaz‐Crettol, Licia Peruzzi, Nathalie Felix, Dario Roccatello, María Jesús Izquierdo Ortiz, R. Chazot, Gabriella Guzzo, Soraya Lavorato, Anne-Laure Kaufmann, Claire Royer-Chardon, Alain Rossier, Luigi Annicchiarico Petruzzelli, Hassib Chehade, Giuseppe Gigliotti, Manuel A. Pascual, Mariangela Ventresca, Carole Gengler, Valentin Rousson, Federica Bocchi, Anne Dufey Teso, Marco Allinovi, Roberta Fenoglio, Cédric Le Caignec, Matteo Barchi, Fádi Fakhouri, Luca Antonucci, Matthieu Perreau, Anne-Claire Brossaud, Francisco Herrera-Gomez, Uyen Huynh-Do, Giorgina Barbara Piccoli, Daniel Teta, Andreas D. Kistler, Min Jeong Kim, the CAIGAN Study Collaborators, Isabella Bassi, Andreas Serra
article en

Abstract

Abstract Background IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide and a leading cause of chronic kidney disease and kidney failure. Increasing evidence supports a central role for complement activation in disease severity and crescent formation. With the emergence of complement-targeted therapies, biomarkers identifying patients with active complement dysregulation are increasingly needed. Methods CAIGAN (Complement Activation in IgA Nephropathy) is an international, prospective, observational multicenter cohort study involving adult and pediatric nephrology centers in Switzerland, Italy, France, and Spain. Consecutive patients undergoing clinically indicated native kidney biopsy for suspected IgAN will be screened, and those with biopsy-proven primary IgAN will be enrolled. Clinical and laboratory follow-up data will be collected from routine care every six months for three years, with additional three-month data included where available. Blood and urine samples for complement analyses will generally be obtained after histopathological confirmation of IgAN, within 4 weeks after kidney biopsy and before initiation of immunosuppressive therapy. In patients with a rapidly progressive clinical course requiring prompt immunosuppressive treatment, sampling may precede histopathological confirmation and will be performed after informed consent and before administration of immunosuppressive agents. Complement profiling will include circulating complement proteins and activation products, functional pathway assessment, and complement-related genetic analyses. Kidney biopsies will be characterized using the Oxford MEST-C classification, with intrarenal complement deposition assessed in a subgroup. The primary objective is to validate prospectively the association observed in our retrospective pilot study between circulating sC5b-9 concentrations and the percentage of active glomerular crescents. Secondary exploratory objectives include characterization of the mechanisms underlying complement activation and dysregulation and evaluation of their associations with clinical phenotype, histopathological findings, renal tissue complement activation, genetic profiles, and longitudinal kidney outcomes. Discussion CAIGAN will integrate complement phenotyping, genetics, histopathology, and prospective clinical follow-up to characterize complement activation across the spectrum of primary IgAN and possibly support the development of biomarker-guided therapeutic strategies.

BMC Nephrology
University of Bern (CH), University of Zurich (CH), University Hospital of Bern (CH), Centre Hospitalier Universitaire Vaudois (CH), Hospital Universitario de Burgos (ES), Ospedale San Giovanni Bosco (IT), Hôpital de Sion (CH), Spital Thurgau (Switzerland) (CH), Hôpital du Valais (CH), University of Turin (IT), University of Lausanne (CH)
Université de Lausanne
Good health and well-being
Renal Diseases and Glomerulopathies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon